Oxidative/antioxidative enzyme-mediated antiproliferative and proapoptotic effects of the GPER1 agonist G-1 on lung cancer cells

Kurt,Akif  Hakan; Çelik,Ahmet; Kelleci,Bekir  Mehmet

doi:10.3892/ol.2015.3711

Oxidative/antioxidative enzyme-mediated antiproliferative and proapoptotic effects of the GPER1 agonist G-1 on lung cancer cells

Authors:
- Akif Hakan Kurt
- Ahmet Çelik
- Bekir Mehmet Kelleci
View Affiliations

Affiliations: Department of Pharmacology, Faculty of Medicine, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey, Department of Biochemistry, Faculty of Medicine, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey, Department of Biology, Faculty of Science and Art, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey
Published online on: September 16, 2015 https://doi.org/10.3892/ol.2015.3711
Pages: 3177-3182

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Estrogen mediates fast signal responses or transcriptional events via G protein-coupled estrogen receptor 1 (GPER1). However, there is no data on the effect of GPER1 on lung cancer cell proliferation and apoptosis. The present study aimed to analyze the anticancer effects of the GPER1 agonist G‑1 on A549 human lung cancer cells. A549 cells were treated with 17β‑estradiol and G‑1, and cell proliferation was analyzed using MTT and WST assays. In addition, the apoptotic effects induced by G‑1 were investigated using acridine orange/ethidium bromide staining. A549 cells were treated with a half maximal inhibitory concentration of G‑1 for 72 h, and nitric oxide (NO) levels and superoxide dismutase (SOD), catalase and glutathione peroxidase (GPx) enzyme activities were analyzed by spectrophotometry. The results revealed that G‑1 significantly decreased cell proliferation. In addition to the antiproliferative effect of G‑1, a marked increase in apoptotic activity was observed when cells were treated with 2x10‑5 M G‑1. Furthermore, G‑1 increased NO levels, and SOD and GPx activity. These findings indicate that the GPER1 agonist G‑1 is able to exert antiproliferative and proapoptotic effects on A549 cells, and that oxidant and antioxidant molecules may mediate these effects.

View Figures

View References

1	Lortet TJ, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E and Bray F: International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 84:13–22. 2014. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
3	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment and survivorship. Mayo Clin Proc. 83:584–594. 2008. View Article : Google Scholar : PubMed/NCBI
4	Wang T, Nelson RA, Bogardus A and Grannis FW Jr: Five-year lung cancer survival: Which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer. 116:1518–1525. 2010. View Article : Google Scholar : PubMed/NCBI
5	Deroo BJ and Korach KS: Estrogen receptors and human disease. J Clin Invest. 6:561–570. 2006. View Article : Google Scholar
6	Donington JS and Colson YL: Sex and gender differences in non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 23:137–145. 2011. View Article : Google Scholar : PubMed/NCBI
7	Meinhold CL, de González Berrington A, Bowman ED, Brenner AV, Jones RT, Lacey JV Jr, Loffredo CA, Perlmutter D, Schonfeld SJ, Trivers GE and Harris CC: Reproductive and hormonal factors and the risk of nonsmall cell lung cancer. Int J Cancer. 128:1404–1413. 2011. View Article : Google Scholar : PubMed/NCBI
8	Cheskis BJ, Greger JG, Nagpal S and Freedman LP: Signaling by estrogens. J Cell Physiol. 213:610–617. 2007. View Article : Google Scholar : PubMed/NCBI
9	Dubey S, Siegfried JM and Traynor AM: Non-small-cell lung cancer and breast carcinoma: Chemotherapy and beyond. Lancet Oncol. 7:416–424. 2006. View Article : Google Scholar : PubMed/NCBI
10	Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O and Fishbein M: Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids. 70:372–381. 2005. View Article : Google Scholar : PubMed/NCBI
11	Luksha L and Kublickiene K: The role of estrogen receptor subtypes for vascular maintenance. Gynecol Endocrinol. 25:82–95. 2009. View Article : Google Scholar : PubMed/NCBI
12	Ullrich ND, Krust A, Collins P and MacLeod KT: Genomic deletion of estrogen receptors ERalpha and ERbeta does not alter estrogen-mediated inhibition of Ca2+ influx and contraction in murine cardiomyocytes. Am J Physiol Heart Circ Physiol. 294:H2421–H2427. 2008. View Article : Google Scholar : PubMed/NCBI
13	Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA and Hathaway HJ: Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol. 70:165–190. 2008. View Article : Google Scholar : PubMed/NCBI
14	Mizukami Y: In vivo functions of GPR30/GPER-1, a membrane receptor for estrogen: From discovery to functions in vivo. Endocr J. 57:101–107. 2010. View Article : Google Scholar : PubMed/NCBI
15	Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, et al: Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2:207–212. 2006. View Article : Google Scholar : PubMed/NCBI
16	Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM and Lau KM: Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21 and induction of G(2) cell-cycle arrest. Cell Death Differ. 17:1511–1523. 2010. View Article : Google Scholar : PubMed/NCBI
17	Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, et al: The G Protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 1:1184–1194. 2010. View Article : Google Scholar
18	Wang C, Lv X, Jiang C and Davis JS: The putative G-protein coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian and breast cancer cells in a GPER-independent manner. Am J Transl Res. 4:390–402. 2012.PubMed/NCBI
19	Tong L, Chuang CC, Wu S and Zuo L: Reactive oxygen species in redox cancer therapy. Cancer Lett. 367:18–25. 2015. View Article : Google Scholar : PubMed/NCBI
20	Kurt AH and Buyukafsar K: Vasoconstriction induced by G1, a G-protein-coupled oestrogen receptor1 (GPER-1) agonist, in the isolated perfused rat kidney. Eur J Pharmacol. 702:71–78. 2013. View Article : Google Scholar : PubMed/NCBI
21	Pektas M, Kurt AH, Un I, Tiftik RN and Buyukafsar K: Effects of 17β-estradiol and progesterone on the production of adipokines in differentiating 3T3-L1 adipocytes: Role of Rho-kinase. Cytokine. 72:130–134. 2015. View Article : Google Scholar : PubMed/NCBI
22	Jala VR, Radde BN, Haribabu B and Klinge CM: Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer. BMC Cancer. 28:612–624. 2012.
23	Ribble D, Goldstein NB, Norris DA and Shellman YG: A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol. 5:122005. View Article : Google Scholar : PubMed/NCBI
24	Aebi H: Catalase in vitro. Methods Enzymol. 105:121–126. 1984. View Article : Google Scholar : PubMed/NCBI
25	Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265–275. 1951.PubMed/NCBI
26	Fridovich I: Superoxide dismutase. Adv Enzymol. 41:35–97. 1974.PubMed/NCBI
27	Levander OA, DeLoach DP, Morris VC and Moser PB: Platelet glutathione peroxidase activity as an index of selenium status in rats. J Nutr. 113:55–63. 1983.PubMed/NCBI
28	Griess JP: Comments on the discussion of the HH. Weselsky and Benedict ‘on some azo compounds’. Ber Deutsch Chem Ges. 12:426–428. 1879.(In German). View Article : Google Scholar
29	Cohen JJ: Apoptosis: The physiological pathway of cell death. Hosp Pract (Off Ed). 15:35–43. 1993.
30	Wang C, Lv X, He C, Hua G, Tsai MY and Davis JS: The G-protein-coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian cancer cells by blocking tubulin polymerization. Cell Death Dis. 4:e8692013. View Article : Google Scholar : PubMed/NCBI
31	Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM and Lau KM: Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21 and induction of G(2) cell-cycle arrest. Cell Death Differ. 17:1511–1523. 2010. View Article : Google Scholar : PubMed/NCBI
32	Young IS and Woodside JV: Antioxidants in health and disease. J Clin Pathol. 54:176–186. 2001. View Article : Google Scholar : PubMed/NCBI
33	Khan MA, Tania M, Zhang DZ and Chen HC: Antioxidant enzymes and cancer. Chin J Cancer Res. 22:87–92. 2010. View Article : Google Scholar
34	Pallepati P and Averill-Bates DA: Activation of ER stress and apoptosis by hydrogen peroxide in HeLa cells: Protective role of mild heat preconditioning at 40°C. Biochim Biophys Acta. 1813:1987–1999. 2011. View Article : Google Scholar : PubMed/NCBI
35	Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, Pelliccia G, Luzi L, Minucci S, Marcaccio M, et al: Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell. 122:221–233. 2005. View Article : Google Scholar : PubMed/NCBI
36	Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM and Castellón EA: Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl. 28:282–293. 2007. View Article : Google Scholar : PubMed/NCBI
37	Khan MA, Chen HC, Wan XX, Tania M, Xu AH, Chen FZ and Zhang DZ: Regulatory effects of resveratrol on antioxidant enzymes: A mechanism of growth inhibition and apoptosis induction in cancer cells. Mol Cells. 35:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
38	Dong WH, Chen JC, He YL, Xu JJ and Mei YA: Resveratrol inhibits K(v)2.2 currents through the estrogen receptor GPR30-mediated PKC pathway. Am J Physiol Cell Physiol. 305:547–557. 2013. View Article : Google Scholar
39	Pacher P, Beckman JS and Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 87:315–424. 2007. View Article : Google Scholar : PubMed/NCBI